Loss of SALL1 Promotes Hepatocellular Carcinoma Growth and Is Associated with Poor Clinical Outcome
Cancers · 24.04.2026 · 18 (9) · 1355
DOI: 10.3390/cancers18091355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 24.04.2026. Verfasst von Yoshifumi Saito und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Program of the National Institutes of Health, National Cancer Institute, CCR.
Abstract (Originalsprache)
Background/Objectives: Hepatocellular carcinoma (HCC) remains a major malignancy with high incidence and mortality, in part due to its diverse etiology and intratumoral heterogeneity, which contributes to drug resistance and frequent recurrence. SALL1 (Spalt-Like Transcription Factor 1), a zinc-finger transcription factor, was reported to function as a tumor suppressor in several cancers, including breast cancer and glioma, and accumulating evidence support its involvement in tumor biology. In this study, the role of SALL1 in HCC was examined.
Methods
Public RNA and protein databases derived from human HCC were interrogated. Western blotting quantification of clinical HCC for SALL1 levels was carried out. Cell culture and xenograft studies were performed using genetically modified HCC tumor cells.
Results
As revealed by pubic RNA and protein database analysis and further western blotting quantification of clinical samples of HCC, SALL1 is decreased in human HCC. The effect of reduced SALL1 expression on the tumorigenic properties and transcriptional regulation in HCC was then examined. Knockdown of SALL1 in the HCC cell lines Huh7 and Hep3B, enhanced cell proliferation in vitro and accelerated tumor growth in a xenograft mouse model, suggesting that lower SALL1 expression increases cell proliferation and tumorigenesis in HCC. RNA-seq and ChIP analyses further identified three novel candidate target genes (SLC6A14, GABRG1, and AKR1B10), suggesting that SALL1 may exert a tumor-suppressive effect, at least in part, through negative regulation of these genes.
Conclusions
These findings establish SALL1 as a possible tumor suppressor and provide new insights into the biological significance of SALL1 downregulation in HCC. SALL1 could be a candidate prognostic marker and a potential therapeutic target.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Laboratory of Metabolism, Division of Molecular Science, Graduate School of Science and Technology, Gunma University, Kiryu 376-8515, Gunma, Japan.
- Key Laboratory of Remodeling-Related Cardiovascular Diseases, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Ministry of Education, Beijing 100069, China.
- Department of General Surgery, Beijing Friendship Hospital, National Clinical Research Center for Digestive Diseases, State Key Laboratory of Digestive Health, Beijing Key Laboratory of Cancer Invasion and Metastasis Re…
- Center for Food Science and Wellness, Gunma University, Maebashi 371-8510, Gunma, Japan.
ORCID-Profile: Carlos Ichiro Kasano-Camones, Xiaoting Yu, Aijuan Qu, Yusuke Inoue
Förderung
- Intramural Research Program of the National Institutes of Health
- National Cancer Institute
- CCR
- CIL
Zitieren
APA
Saito, Y., Kasano-Camones, C. I., Tamura, A., Kimura, S., Yu, X., Cui, Y., Sawaswong, V., Krausz, K. W., Wang, D., Qu, A., Inoue, Y., Takahashi, S., & Gonzalez, F. J. (2026). Loss of SALL1 Promotes Hepatocellular Carcinoma Growth and Is Associated with Poor Clinical Outcome. Cancers, 18(9), 1355. https://doi.org/10.3390/cancers18091355
Vancouver
Saito Y, Kasano-Camones CI, Tamura A, Kimura S, Yu X, Cui Y, et al. Loss of SALL1 Promotes Hepatocellular Carcinoma Growth and Is Associated with Poor Clinical Outcome. Cancers. 2026;18(9):1355. doi:10.3390/cancers18091355
BibTeX
@article{Saito2026,
author = {Saito, Yoshifumi and Kasano-Camones, Carlos Ichiro and Tamura, Atsumi and Kimura, Shioko and Yu, Xiaoting and Cui, Yutong and Sawaswong, Vorthon and Krausz, Kristopher W and Wang, Dong and Qu, Aijuan and Inoue, Yusuke and Takahashi, Shogo and Gonzalez, Frank J},
title = {Loss of SALL1 Promotes Hepatocellular Carcinoma Growth and Is Associated with Poor Clinical Outcome},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1355},
doi = {10.3390/cancers18091355}
}
EUVIMED